Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004

robot
Abstract generation in progress

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), sold 3,639 shares of Common Stock at $65.00 per share on March 31, 2026. Following this transaction, Callos directly holds 66,004 shares of Cytokinetics Common Stock. This open-market sale, detailed in a Form 4 filing, amounted to $236,535.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin